Background: There is little data on mycophenolic acid (MPA) pharmacokinetics and pharmacogenomics and optimal MPA exposure in lupus nephritis (LN) patients during long-term maintenance.
Methods: We measured blood MPA levels at 1, 2, 4, 8, 10 and 12-h post-dose (i.e.